CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. (CPD-DARA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04667663 |
|
Recruitment Status :
Recruiting
First Posted : December 16, 2020
Last Update Posted : January 25, 2023
|
Sponsor:
Cancer Trials Ireland
Collaborators:
Janssen Pharmaceuticals
Celgene
Information provided by (Responsible Party):
Cancer Trials Ireland
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Actual Primary Completion Date : | April 29, 2022 |
| Estimated Study Completion Date : | April 30, 2026 |